N-Acetyl Selank Amidate: Evidence, Mechanism & Legal Status

N-Acetyl Selank Amidate ("NA-Selank," sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2) is marketed as an upgraded, longer-acting version of Selank — the tuftsin-derived heptapeptide developed in Russia as a non-sedating anxiolytic and mild nootropic.6 Its appeal in nootropic communities is the promise of Selank's calm-without-sedation profile with better stability. Its proof, for the modified molecule, is nonexistent. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. N-Acetyl Selank Amidate is not an FDA-approved drug; it is sold as a "research chemical not for human use." Dosing figures are reported strictly as seen in the published literature for the parent peptide, for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is N-Acetyl Selank Amidate and how does it work?

Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, built by elongating the natural immunomodulatory tetrapeptide tuftsin (a fragment of the IgG heavy chain) with a C-terminal Pro-Gly-Pro extension; that extension was the original stabilization strategy, conferring resistance to peptidase cleavage and a longer duration than tuftsin.2 N-Acetyl Selank Amidate adds two further terminal protections to that backbone: an N-terminal acetyl group that shields against aminopeptidases and a C-terminal amide that blocks carboxypeptidases, giving Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2.6 Vendor chemistry data report a molecular formula of C35H59N11O10, a molecular weight near 793.9 Da, and CAS 864070-44-0 — supplier-catalog figures, not values from a peer-reviewed pharmacokinetic paper.78

The stability rationale is sound in principle but unmeasured in fact. Terminal acetylation and amidation are well-established, sequence-general tactics to slow exopeptidase degradation, yet for NA-Selank no measured half-life exists; sources transparently state that direct kinetic comparison data are absent and the improvement is hypothesized by analogy.6 For context, parent Selank's own plasma half-life is reported only in the minutes range, while its downstream anxiolytic effects last hours because they are driven by gene-expression changes, active metabolites, and enkephalinase inhibition rather than circulating peptide.2 Marketing claims that NA-Selank's half-life jumps to "200-300 minutes" or "2-5x Selank" appear only in vendor copy without a primary citation.6

Because the acetyl and amide caps do not alter the core target-binding domain, NA-Selank is assumed to share Selank's mechanism — but this is unconfirmed for the analog.6 For parent Selank the best-characterized actions are positive allosteric modulation of the GABAergic system (it shifts GABA binding and GABAergic gene expression and behaves benzodiazepine-like without binding the benzodiazepine site), dopaminergic and plasticity-gene modulation, enkephalinase inhibition that stabilizes endogenous leu-enkephalin, BDNF upregulation with neuroprotection in rat models, and tuftsin-derived immunomodulation.214 Parent Selank is used intranasally, exploiting nose-to-brain transport; NA-Selank vendors assume the same route without analog-specific absorption data.5

What is the evidence by indication?

Every indication below rests on parent Selank data. For N-Acetyl Selank Amidate specifically there are zero human studies and zero living-animal studies — its effects "remain almost entirely unknown and are only theoretical."5 The analog is therefore graded D across the board; the Selank grades are shown for context and do not transfer.

The anchor human study compared Selank (n=30) to the benzodiazepine medazepam (n=32) in 62 patients with generalized anxiety disorder or neurasthenia, using Hamilton, Zung, and CGI scales: anxiolytic effects were comparable to medazepam, while Selank added antiasthenic and psychostimulant effects and raised serum leu-enkephalin stability.1 A response-timing analysis reported roughly 40% rapid responders, with HAM-A falling sharply within one to three days.3 The caveats keep even the parent at grade B, never grade A: small samples, Russian-only psychiatric populations, largely non-English publications, no independent Western replication, and no placebo-controlled Western RCT.15 For interested readers, no registered Western trial of either compound appears on the federal registry at ClinicalTrials.gov — the absence is itself informative.

For cognition, rodent studies show improved associative learning, spatial memory, and attention under distraction, attributed to BDNF-mediated hippocampal plasticity, while the human anxiety trials noted preserved cognition versus benzodiazepine slowing — an absence of impairment rather than a robust pro-cognitive effect.41 For neuroprotection and immunomodulation, animal and in-vitro work shows reduced pro-inflammatory cytokines under stress and broad transcriptomic changes, with no qualifying human efficacy data and nothing on NA-Selank.2

What doses appear in the literature?

Reported strictly as information, not a protocol. There is no published dosing literature for N-Acetyl Selank Amidate, because no study has ever administered it.5 The figures that circulate are the parent Selank clinical regimen plus vendor extrapolations. In Russian clinical use, intranasal Selank is given at roughly 300 micrograms two to three times daily (about 600-900 micrograms per day) as an approved 0.15% nasal spray, typically in courses of around 10 to 14 days.15 NA-Selank suppliers describe intranasal microgram dosing in the same general range or lower, reasoning that the longer assumed half-life could permit less frequent administration — explicitly speculative, with no kinetic study to justify any specific amount or interval.67 As a lyophilized research peptide, vendor handling guidance mirrors generic peptide practice (reconstitute with bacteriostatic water, refrigerate, protect from light) — a handling instruction, not evidence of safe human dosing.7 The honest reading: any NA-Selank "dose" is borrowed from Selank and unvalidated for the analog.

How safe is N-Acetyl Selank Amidate?

Analog-specific safety is simply unknown: there is no toxicology, no adverse-event reporting, and no interaction data for the modified compound.5 The available picture is borrowed from parent Selank, where human and preclinical data describe low toxicity with no serious adverse events; the most common complaint is mild nasal or mucosal irritation, with occasional headache, and a recurrent non-sedating, non-dependence-forming profile with no withdrawal, tolerance, or amnesia.51 A speculative concern of GABA-receptor desensitization causing paradoxical anxiety or insomnia with chronic use is raised online but has no empirical support.7 Because Selank touches GABAergic and serotonergic signaling, a theoretical additive or interaction risk with benzodiazepines, other GABAergics, or serotonergic agents such as SSRIs is plausible and unstudied for the analog — a reason for caution rather than a documented event.2 No formal contraindications are established; conservative default exclusions are pregnancy and lactation, children and adolescents, and anyone with uncontrolled psychiatric illness, alongside the broader caution against any human use of a research chemical.5

What is the FDA and WADA status in 2026?

Neither Selank nor N-Acetyl Selank Amidate is an FDA-approved drug; NA-Selank is sold as a research chemical labeled "not for human use" and is unscheduled in the US.57 In April 2026 the FDA removed 12 peptides — including parent Selank — from compounding Category 2, after nomination withdrawals.9 Crucially, removal from Category 2 did not place Selank on the 503A Bulks List or grant Category 1 status; with the exception of GHK-Cu, these peptides remain in a regulatory gray zone awaiting Pharmacy Compounding Advisory Committee review, and compounding them carries enforcement risk.910 The July 23-24, 2026 PCAC agenda covers BPC-157, KPV, TB-500, MOTS-C, Semax, Epitalon, and DSIP — Selank is not on that agenda, underscoring its unresolved status — and the N-acetyl-amidate analog is a distinct molecule with no compounding pathway of its own.11

For athletes the conservative reading is clear. Neither Selank nor NA-Selank is explicitly named on the 2026 WADA Prohibited List (in force January 1, 2026), but as a non-approved substance it is plausibly captured by the S0 catch-all, which covers any pharmacological substance with no approved-for-human-use pathway.12 WADA applies strict liability, so the safe position is to treat NA-Selank as prohibited; DEA scheduling is none — it is unscheduled.1213

Bottom line. For the modified form, the honest grade is D — unproven. There are no human trials, no living-animal studies, and no pharmacokinetic measurements on N-Acetyl Selank Amidate; do not infer that Selank's human results apply to it. The parent peptide has limited but real human evidence for anxiety and preclinical support for neuroprotection, and the terminal-cap modification is chemically reasonable — but reasonable is not proven. Treat NA-Selank as an experimental research chemical, not a therapy. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.